Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
TRANSCEND-T2D-1: Diabetes-Specific Phase 3 Data (June 2026) Separate from the TRIUMPH obesity program, Eli Lilly runs TRANSCEND-T2D a dedicated Phase 3 program for type 2 diabetes
When Does Eden Fit Your Situation
A retrospective analysis of 461,382 adults treated with GLP-1 receptor agonists found that nutritional deficiencies were diagnosed in 12.7% of patients within six months and 22.4% within twelve months, with vitamin D deficiency the most common at roughly 13.6% by the one-year mark
Experts warn that colder temperatures can pose risks when it comes to storing weight-loss injections
K.et al (2020)
This combined mechanism of action of GLP-1 makes GLP-1 attractive for the treatment of T2DM
US$ 20.34
US$ 26.06
US$ 27.20
US$ 23.39
